Pharming Group N.V annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Depreciation & Amortization Growth & History (PHAR)
Pharming Group N.V's depreciation and amortization was $7.9M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.9M | $168,000 | +2.16% |
| 2024 | 2024-12-31 | $7.8M | $408,000 | +5.54% |
| 2023 | 2023-12-31 | $7.4M | $1.4M | +24.47% |
| 2022 | 2022-12-31 | $5.9M | −$473,000 | −7.40% |
| 2021 | 2021-12-31 | $6.4M | $338,000 | +5.58% |
| 2020 | 2020-12-31 | $6.1M | $1.1M | +21.16% |
| 2019 | 2019-12-31 | $5.0M | — | — |
Pharming Group N.V quarterly depreciation and amortization
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.0M | $336,000 | +12.44% |
| Q1 2026 | 2026-03-31 | $3.1M | — | — |
| Q4 2025 | 2025-12-31 | $3.2M | — | — |
| Q3 2025 | 2025-09-30 | $2.7M | — | — |
| Q2 2025 | 2025-06-30 | $2.7M | — | — |
Pharming Group N.V depreciation and amortization trends
Over the last five fiscal years, Pharming Group N.V's depreciation and amortization increased from $6.1M to $7.9M, a change of $1.9M. The latest reported quarter, Q2 2026, shows $3.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...